Wedbush Starts Comerica (CMA) at Neutral
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Wedbush initiates coverage on Comerica (NYSE: CMA) with a Neutral rating and a price target of $49.00.
Analyst Peter Winter commented, "We believe CMA is fairly valued as it’s trading at a 16% premium to our regional bank peers, the highest P/E multiple in our group. Although profitability (ROE, ROA and efficiency) is below peers, we believe the premium is warranted as CMA is under-earning in this low rate environment, plus we are forecasting above-average EPS growth in 2017 and 2018 with the implementation of its new GEAR Up initiative."
Shares of Comerica closed at $49.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Union Pacific (UNP) PT Raised to $102 at Stifel Following 4Q Report
- UPDATE: Benchmark Starts Cross Country Healthcare (CCRN) at Buy
- Union Pacific (UNP) PT Raised to $120 at Aegis Capital Following Solid 4Q
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!